We bring advanced treatments to more people, enabling a fair chance at healthier, longer lives
The first immunotherapy approved by major global regulators for recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). In India, it introduces immuno-oncology as a first-line treatment for RM-NPC in combination with chemotherapy.
Our first biosimilar approved and launched in the UK. It is a treatment for several types of cancer, including colorectal, lung, brain, kidney, cervical, and ovarian cancers. Bevacizumab works by blocking a protein called VEGF, slowing the growth and spread of cancer.
A long-acting, USFDA-approved treatment for HIV-1 infection. Our work with Lenacapavir supports our goal to expand HIV treatment and prevention, especially in high-burden regions. We aim to manufacture and commercialise Lenacapavir across 120 countries, in partnership with Gilead Sciences.
We operate across four main segments: Generics (branded, unbranded, and biosimilars), API & Services (development, manufacturing, and research support), Innovative Medicines (NCEs, NBEs, and Cell and Gene therapies), and Consumer Health (OTC products, nutraceuticals, and nicotine replacement solutions). We are also expanding through in-licensing, strengthening our nutrition portfolio, and focusing on public health.
Our programs go beyond medicine, offering guidance, care, and support to make each step easier for patients
A patient support program where gastroenterologists help people with ulcerative colitis better understand and manage Inflammatory Bowel Disease through personalised guidance on diet, exercise, and stress.
betaCare is an initiative by betapharm that helps patients in Germany with useful health information and support. It also offers certified online courses to help improve patient care, and help them navigate treatment and the healthcare system.
A support program for people living with osteoarthritis by helping them understand how to care for their joints. These doctor-led sessions help patients learn about the right exercises, healthy habits, and ways to manage pain, and stay active.
We aspire to improve the lives of patients by ensuring access to quality cancer medicines through accelerated innovation and strong partnerships
"Our mission is to turn
scientific possibilities into real hope,
addressing urgent patient needs
and helping improve lives."
Countries
Active US Abbreviated New Drug Applications (ANDAs)
Active US Drug Master Files (DMFs)
Patients Reached (FY'25)
We aim to ease the burden of disease by helping deliver effective treatments faster, and at lower cost
Skorolox is the first loxoprofen INN available in Russia. It is used to relieve symptoms of acute upper respiratory tract infections, and to treat musculoskeletal and postoperative pain.
A novel drug launched in India to protect newborns and infants from lung infections caused by Respiratory Syncytial Virus in the first season of exposure.
A new medicine approved in India to treat chronic constipation, offering better results and improved comfort compared to existing options.
"Our partners choose us because we stand
for doing the right thing. We operate in
a compliant and sustainable environment,
have built capabilities in complex science,
and are commited to accelerating access
to 1.5bn+ patients."
We work together with our partners to bring healthcare solutions across communities
Working to develop an injectable contraceptive for low and middle income countries, advancing women's health, improving family planning options, and reducing health inequities.
Partnering to distribute pediatric and adult vaccines in India, expanding immunization coverage, and strengthening disease prevention.
Collaborating to expand access to essential cancer therapies approved for more than 40 types of cancer, strengthening oncology care and supporting patients with high-burden diseases worldwide.
Our teams are solving complex challenges with science and technology, keeping patients at the core
"We have a well-developed research pipeline in India, with a primary focus on cancer treatments."
"In the next 10-20 years the field of cell and gene therapy is going to evolve significantly."
"Complex injectables like peptides are redefining patient care, and we’re at the forefront of that transformation."
"Quality is pervasive.
It's in how we work,
how we think, and in the
culture of doing things right.
When that mindset is shared,
everyone becomes responsible for quality."
"Quality is pervasive.
It's in how we work,
how we think, and in the
culture of doing things right.
When that mindset is shared,
everyone becomes responsible for quality."
We continue working towards reducing our environmental footprint, addressing ecological risks from our operations, and are progressing towards carbon neutrality
By implementing initiatives such as wastewater recovery, grey water use, and more, we reduced freshwater consumption by ~70,000 KL from April to September 2023.
By conducting site-level climate risk assessments and improving supplier engagement by sustainable procurement, we identified key vulnerabilites and reduced Scope 3 emissions intensity by 31% since FY2023.
By implementing cost improvement projects and strengthening site-level waste checks, we achieved 20-22% reduction in waste across 9 high-volume products.
By replacing fossil fuels with biofuels in boilers and expanding solar, wind, and hybrid energy use, we reduced Scope 1 and 2 emissions by 33% vs FY2023. Energy-saving initiatives also helped avoid 8,073 tonnes of CO₂ and saved 7.75 million kWh in FY2025.
Discover the science behind our products and how we work towards making a difference in patients' lives
Our products span across Generics, API & Services, Innovation Medicines, and Consumer Health.
